Powerful Science – Meaningful Medicines – Changing Lives | 89bio
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/26/2024 PRESS RELEASE 89bio to Participate in the 7th Annual Evercore HealthCONx Conference
Powerful Science – Meaningful Medicines – Changing Lives - 89bio
Dr. Hank Mansbach is chief medical officer of 89bio. Dr. Mansbach has more than 20 years of clinical, regulatory, and medical affairs experience working across all stages of product development in a wide range of disease states.
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public …
SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten ...
89bio Presents New Analyses Evaluating Pegozafermin and …
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced new analyses of data from the Phase 2b ENLIVEN trial evaluating pegozafermin in ...
89bio Reports Third Quarter 2023 Financial Results and Provides ...
SAN FRANCISCO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the third quarter ended September 30, 2023.
89bio Reports Fourth Quarter and Full Year 2023 Financial Results …
SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the fourth quarter and full year ended December 31 ...
89bio Reports Positive Top-line Data from Phase 1 Single …
San Francisco, California and Herzliya, Israel, May 22, 2019 – 89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today announced positive top-line results from a Phase 1 single ascending dose (SAD) study of its investigational medicine, BIO89-100, in ...
89bio Reaches Alignment with the FDA and EMA on Phase 3 …
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024 —Alignment reached on key elements of the NASH development strategy, including accelerated approval pathway for both F4 and F2-F3 NASH patients using histology—
89bio Reports Second Quarter 2022 Financial Results and Provides ...
SAN FRANCISCO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended June 30, 2022.
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public …
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten ...